Lead switching to resolve undersensing of ventricular tachycardia by a cardiac resynchronization therapy defibrillator

A 63‐year‐old man was admitted to the hospital due to ventricular tachycardia (VT) undersensing, caused by decreased R‐wave amplitude in a cardiac resynchronization therapy defibrillator. The R‐wave amplitude of VT sensed by the left ventricular (LV) lead was markedly higher than that by the right ventricular (RV) lead; therefore, we reconnected the IS‐1 RV lead to the LV IS‐1 port and the IS‐1 LV lead to the RV IS‐1 port to resolve this issue. After discharge, it was confirmed that VT was successfully terminated by the second sequence of intrinsic ATP (iATP, Medtronic, Minneapolis, MN, USA) from the LV lead.

[1]  T. Mitsuhashi,et al.  JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. , 2021, Circulation journal : official journal of the Japanese Circulation Society.

[2]  T. Noda,et al.  Undersensing of ventricular fibrillation by a biventricular implantable cardioverter‐defibrillator: What is the cause and the troubleshooting? , 2019, Journal of arrhythmia.

[3]  Jorge G. Quintanilla,et al.  Ventricular fibrillation undersensing to calculate a safety threshold for baseline rhythm R-wave amplitudes. , 2018, Journal of electrocardiology.

[4]  Michael J Ackerman,et al.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Journal of the American College of Cardiology.

[5]  Chad M. House,et al.  Management of functional Sprint Fidelis leads at cardiac resynchronization therapy-defibrillator generator replacement: a novel option for preventing inappropriate shocks from lead failure in fragile patients with high risk of sudden death† , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[6]  M. Shoda,et al.  2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. , 2017, Heart rhythm.

[7]  J. Rojo-álvarez,et al.  Safety threshold of R-wave amplitudes in patients with implantable cardioverter defibrillator , 2016, Heart.